Bolt Biotherapeutics (NASDAQ:BOLT) Releases Earnings Results, Misses Expectations By $0.04 EPS

Bolt Biotherapeutics (NASDAQ:BOLT) posted its quarterly earnings data on Tuesday. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.04), Zacks reports. Bolt Biotherapeutics had a negative net margin of 665.56% and a negative return on equity of 69.46%. The firm had revenue of $1.14 million for the quarter, compared to the consensus estimate of $1.02 million.

Bolt Biotherapeutics Stock Up 0.9 %

Shares of BOLT stock opened at $0.62 on Friday. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.16 and a quick ratio of 4.28. Bolt Biotherapeutics has a one year low of $0.55 and a one year high of $1.56. The company’s 50-day moving average is $0.64 and its 200 day moving average is $0.74.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “neutral” rating on shares of Bolt Biotherapeutics in a report on Wednesday. Five investment analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $3.50.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.